Overview
Development Programs
Differentiated prodrug candidates initially targeting established IBD market with potential to address shortcomings of existing therapies
❯ More
Your tooltip content goes here
PALI-2108 (PDE4 prodrug, once daily)
Indication
Ulcerative Colitis (UC)
Status
Phase 1b
Highlights
Completed and reported topline data for Ph1
Topline data for UC cohort released
IND and Ph1b/2a expected to commence in H1 2026
Indication
Fibrostenotic Crohn’s Disease (FSCD)
Status
Phase 1B
Highlights
Completed and reported topline data for Ph1
Ph1b cohort in FSCD ongoing and topline reported Q1 2026
Ph2a expected to commence in H2 2026
PDE4 Platform
Precision Medicine Approach
Sign Up For Alerts